Jeremiah Brown, MD
Retina Specialist · Schertz, TXNPI 1891702163
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Genentech USA, Inc. at 36.3% of the total. Among retina specialist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 479 payments — averaging $707.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$123K
- Apellis Pharmaceuticals, Inc.$70K
- Astellas Pharma US Inc$40K
- Genentech, Inc.$33K
- US Retina LLC$33K
- Spark Therapeutics, Inc.$19K
- plus $20K from 24 others
Across 816 payments — averaging $3303.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.5M
- Regeneron$556K
- Boehringer Ingelheim$393K
- F. Hoffmann-la Roche AG$123K
- Apellis Pharmaceuticals, Inc.$79K
- AbbVie$25K
- plus $26K from 3 others
What the payments were for
- Consulting fees$56,39217%
- Speaking & faculty fees$191,88157%
- Travel & lodging$37,00611%
- Food & beverage$18,5525%
- Education$1180%
- Gifts$1,7821%
- Ownership interest$13,1094%
- Other$19,9556%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 150 | $122,891 |
| Apellis Pharmaceuticals, Inc. | 65 | $70,087 |
| Astellas Pharma US Inc | 46 | $39,932 |
| Genentech, Inc. | 21 | $33,400 |
| US Retina LLC | 7 | $33,064 |
| Spark Therapeutics, Inc. | 18 | $19,372 |
| AbbVie(2 entities) | 33 | $3,908 |
| Heidelberg Engineering, Inc. | 4 | $3,410 |
| Eyepoint US, Inc. | 10 | $2,539 |
| Ocular Therapeutix, Inc. | 2 | $2,028 |
| Carl Zeiss Meditec, Inc. | 3 | $1,821 |
| Regeneron Healthcare Solutions, Inc. | 28 | $1,075 |
| Alimera Sciences, Inc. | 3 | $1,061 |
| Alcon | 11 | $810 |
| Harrow Eye, LLC | 9 | $635 |
| Novartis | 11 | $622 |
| Regeneron | 7 | $485 |
| Biotissue Holdings Inc. | 2 | $300 |
| Biogen | 13 | $273 |
| Medline Industries LP | 19 | $236 |
| Alcon Research LLC | 1 | $182 |
| Amgen(2 entities) | 2 | $137 |
| Mallinckrodt Hospital Products Inc. | 1 | $100 |
| ANI Pharmaceuticals, Inc. | 4 | $97 |
| Dutch Ophthalmic, USA | 1 | $92 |
| Carl Zeiss Meditec USA, Inc. | 1 | $89 |
| Bausch & Lomb Americas Inc. | 4 | $82 |
| US Oncology Corporate, Inc. | 1 | $25 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$338,795 in reported general payments places this provider in the 95th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 12 | $7,811 |
| Prednisolone Acetate | 109 | $4,952 |
| Brimonidine Tartrate | 86 | $3,606 |
| Bromfenac Sodium | 34 | $3,443 |
| Ketorolac Tromethamine | 116 | $2,973 |
| Difluprednate | 31 | $2,846 |
| Atropine Sulfate | 76 | $2,652 |
| Gatifloxacin | 48 | $1,698 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 95 | $1,526 |
| Bepotastine Besilate | 12 | $1,266 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 13 | $984 |
| Latanoprost | 71 | $868 |
| MoxifloxacinMoxifloxacin Hcl | 28 | $850 |
| Dorzolamide Hcl | 32 | $597 |
| Timolol Maleate | 69 | $459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $3,908 | $7,81112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 108 retina specialist providers in Texas.
Other retina specialist in Schertz
- Courtney CrawfordBurleson$342K
- Victor GonzalezMcAllen$335K
- Judy KimDallas$256K
- Emmanuel ChangBellaire$254K
- Ting Fang SuarezBellaire$156K
- Hemang PandyaPlano$153K
- Margaret RunnerSouthlake$71K
- Moises ChicaSan Antonio$43K
- Garvin DavisHouston$38K
- Brian BergerAustin$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.